Johnson & Johnson Submits Schizophrenia Drug CAPLYTA sNDA to FDA Based on Positive Relapse Prevention Data
unknown
📅 Published: 2025-07-10 15:40
📰 Source: Yahoo
📝 Words: 56
📝 Article Content
Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for its schizophrenia drug called CAPLYTA (lumateperone). The submission is based on long-term Phase 3 clinical data demonstrating CAPLYTA’s safety and […]
📄 Summary
Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for its schizophrenia drug called CAPLYTA (lumateperone). The submission is based on long-term Phase 3 clinical data demonstrating CAPLYTA’s safety and […]
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-07-10 16:42:22
Updated At:
2025-07-10 16:42:22
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A
NOW - ServiceNow Inc.
Relevance: N/A